top of page
  • Active, not recruiting

NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With RRMM

Updated: Apr 25, 2022

NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma


cart myeloma china

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.


Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator: CARsgen Therapeutics Co., Ltd.



ClinicalTrials.gov Identifier: NCT03380039


Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma


Click here for details on Clinicaltrials.gov

 

CART - BCMA : National Cancer Institute